普罗布考对急性冠状动脉综合征患者的抗炎抗氧化作用

Antiinflammation and antioxidation effect of probucol in patients with acute coronary syndrome

目的观察普罗布考对急性冠状动脉综合征(ACS)患者氧化低密度脂蛋白胆固醇(ox-LDL-C)、基质金属蛋白酶(MMP)-9和超敏感C反应蛋白(hs-CRP)水平的影响,探讨普罗布考的抗炎抗氧化作用。方法随机将60例ACS患者分入两组(每组30例):常规治疗组患者予常规治疗;普罗布考组患者在常规治疗的基础上加口服普罗布考0.375g/次,2次/d,治疗时间为12周。分别于服药前后检测血ox-LDL-C、MMP-9、hs-CRP水平。结果两组患者治疗前的ox-LDL-C、MMP-9、hs-CRP水平均高于正常值,两组间的差异均无统计学意义(P值均>0.05)。普罗布考组治疗后的ox-LDL-C、MMP-9、hs-CRP水平均显著低于同组治疗前和常规治疗组治疗后(P值均<0.01),常规治疗组治疗前后上述指标的差异均无统计学意义(P值均>0.05)。结论普罗布考可显著降低ACS患者的ox-LDL-C、MMP-9和hs-CRP水平,提示其具有较强的抗炎、抗氧化和抗动脉粥样硬化的作用。

Objective To explore the antiinflammation and antioxidation effect of probucol in the patients with acute coronary syndrome （ACS） by observing the changes of the plasma levels of oxidized low-density lipoprotein （ox-LDL-C）, matrix metalloproteinase-9 （MMP-9） and high sensitivity C-reactive protein （hs-CRP）. Methods Sixty ACS patients were randomly divided into two groups （n = 30）. The subjects in control group received conventional therapy and those in probucol group received conventional therapy and probucol 0. 375 g twice daily. The total period of treatment was 12 weeks. The plasma levels of ox-LDL-C, MMP-9 and hs-CRP were examined before and after treatment. Results The plasma levels of ox-LDL-C, MMP-9 and hs-CRP of 60 ACS patients were higher than normal values, but there were no significant differences between groups （all P〉 0.05）. The plasma levels of ox-LDL-C, MMP-9 and hs-CRP after treatment in the prebucol group were significantly lower than those before treatment and those after treatment in the control group （all P〈0.01 ）. There were no significant differences in the plasma levels of ox-LDL-C, MMP-9 or hs-CRP in the control group before and after treatment （all P〉0.05）. Conclusion Probucol can effectively reduce the plasma levels of ox-LDL-C, MMP-9 and hs-CRP in ACS patients. These results indicate that probucol has good antiinflammation, antioxidation and anti- atherosclerosis. （Shanghai Med J, 2014, 37.. 574-576）